<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT138903013991N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2009-03-21</date_registration>
      <primary_sponsor>Iran University of Medical Science</primary_sponsor>
      <public_title>Comparison of co-administration of clonidine and pethdine with bupivacaine during spinal anesthesia</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of co-administration of clonidine and pethdine with bupivacaine during spinal anesthesia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2009-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/4162</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Spinal anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: Spinal anesthesia with 15 mg Bupivacaine 0.5%. Intervention 2: Spinal anesthesia with 0.75 mg/kg pethidine + 0.75 microgram/kg clonidine.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Reza Salmanian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Niayesh st., Satarkhan ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 6435 2326</telephone>
        <email>salmanian@gmail.com</email>
        <affiliation>Iran university of medical sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farnad Imani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Niayesh st., Sattarkhan Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 6435 2344</telephone>
        <email>farimani@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: Patients in class I or II ASA are selected for surgery in lower limbs at Rasoule akram Hospital. &#13;
Exclusion criteria: Any known contraindication for spinal anesthesia, such as increased intracranial pressure, neurological disorders, hemorrhagic diathesis, or infection at the puncture site, disorientation, bilateral lower limb Fx., pelvic Fx., diabetes mellitus, miteral stenosis, aortic stenosis, allergy to bupivacaine or clonidine or pethidine.</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Y48.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Anaesthetic, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Spinal anesthesia with 15 mg Bupivacaine 0.5%</i_keyword>
      <i_keyword>Spinal anesthesia with 0.75 mg/kg pethidine + 0.75 microgram/kg clonidine</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Systolic Blood Pressure. Timepoint: First 10 minutes: every 2 minutes, next 10 minutes: every 3 minutes and next 160 minutes: every 5 minutes. Method of measurement: With automatic BP indicator.</prim_outcome>
      <prim_outcome>Level of sensory block. Timepoint: First 10 minutes: every 2 minutes, next 10 minutes: every 3 minutes and next 160 minutes: every 5 minutes. Method of measurement: Evaluation for level of sensory block at different dermatome with blunt needle fo e.</prim_outcome>
      <prim_outcome>Motor Block. Timepoint: First 10 minutes: every 2 minutes, next 10 minutes: every 3 minutes and next 160 minutes: every 5 minutes. Method of measurement: 1=unable to move hip, 2=unable to move knee and 3=unable to move foot.</prim_outcome>
      <prim_outcome>Sedation rate. Timepoint: First 10 minutes: every 2 minutes, next 10 minutes: every 3 minutes and next 160 minutes: every 5 minutes. Method of measurement: 0=anxiet, 1=awake and calm, 2=Sleepy, 3=Sleepy and responsive to sound, 4=Sleepy and responsive to painfull stimuli, 5=Unresponsive.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: First 10 minutes: every 2 minutes, next 10 minutes: every 3 minutes and next 160 minutes: every 5 minutes. Method of measurement: ECG monitoirg.</prim_outcome>
      <prim_outcome>Analgesic request. Timepoint: Every 1 hour for 24 hours. Method of measurement: Patient's request.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Vomitting. Timepoint: First 10 minutes: every 2 minutes, next 10 minutes: every 3 minutes and next 160 minutes: every 5 minutes. Method of measurement: Observation.</sec_outcome>
      <sec_outcome>Bradicardia. Timepoint: First 10 minutes: every 2 minutes, next 10 minutes: every 3 minutes and next 160 minutes: every 5 minutes. Method of measurement: ECG monitoirg.</sec_outcome>
      <sec_outcome>Nausea. Timepoint: First 10 minutes: every 2 minutes, next 10 minutes: every 3 minutes and next 160 minutes: every 5 minutes. Method of measurement: Observation.</sec_outcome>
      <sec_outcome>Hypotension. Timepoint: First 10 minutes: every 2 minutes, next 10 minutes: every 3 minutes and next 160 minutes: every 5 minutes. Method of measurement: Observation on Monitoring of Blood pressur indicator.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Science</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2009-02-21</approval_date>
        <contact_name>Iran University of Medical Sciences</contact_name>
        <contact_address>Hemmat Expway, Iran University of Medical Sciences Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
